Significant fluctuations are estimated for all segments in the online OTC pharmaceuticals market over the forecast period in the United Kingdom. Overall, the revenue follows a positive trend, as there are more increasing values than decreasing values expected in the individual segments until 2029. Among them, the segment Analgesics achieves the relatively highest value throughout the entire period, reaching ****** million U.S. dollars.

The United Kingdom OTC Drugs Market Report is Segmented by Product Type (cough, Cold, and Flu Products, Analgesics, Dermatology Products, Gastrointestinal Products, and Other Product Types), Route of Administration (oral, Topical, and Parenteral), and Distribution Channel (retail Pharmacy, Hospital Pharmacy, and E-Pharmacy). The Report Offers the Value (in USD) for the Above Segments.

The total sales value of over-the-counter (OTC) drugs amounted to over ************ British pounds in 2024. OTC refers to a class of medication that can be sold without the need for a prescription. Pain relief garnered the highest sales value at some *** million British pounds, followed by cough, cold, and sore throat remedies at some *** million British pounds. Prescribed medication At the same time as the OTC market has been increasing, the number of prescription items dispensed has likewise increased in the same period. In 2023/24, there were **** billion items dispensed in England alone. As a result, the average number of prescription items dispensed per month at pharmacies in England stood at over ***** in 2023/24. Leading brands in the market In the UK, one of the leading adult oral analgesic (also known as painkillers) brands by sales value was Nurofen with annual sales of more than ********** British pounds. The pediatric analgesic market was dominated by Calpol, with annual sales of more than ********** British pounds.

The United Kingdom Over-the-Counter (OTC) drug market, valued at approximately £4.83 billion in 2025, exhibits a robust Compound Annual Growth Rate (CAGR) of 4.86% from 2025 to 2033. This growth is fueled by several key factors. Increasing prevalence of chronic conditions like allergies and gastrointestinal issues necessitates greater self-medication, driving demand for OTC products. The aging population in the UK further contributes, as older individuals frequently require OTC medications for managing age-related ailments. Furthermore, the rising adoption of e-pharmacies expands market access and convenience, stimulating sales. However, stringent regulatory frameworks and price controls could act as potential restraints on market expansion. Segment-wise, the Cough, Cold, and Flu segment is expected to maintain its dominance, given the cyclical nature of respiratory illnesses. Analgesics, driven by widespread aches and pains, will also constitute a substantial market share. The rising awareness of skin health is poised to fuel growth within the Dermatology Products segment. Major players such as Bayer AG, Haleon, Johnson & Johnson, and Pfizer actively shape market competition through brand building, innovation, and strategic partnerships. The retail pharmacy channel currently holds a significant market share, though the e-pharmacy segment shows considerable growth potential due to its accessibility and affordability. The forecast period (2025-2033) projects continued expansion, with a substantial increase in market value. The CAGR suggests a consistent rise in demand driven by both population dynamics and evolving healthcare trends. Innovation in formulations and delivery systems, catering to consumer preferences for convenience and efficacy, will be crucial for market players to maintain competitiveness. The ongoing emphasis on public health awareness campaigns may further propel the market's growth. However, fluctuations in economic conditions and potential shifts in healthcare policies could influence the market's trajectory. Competitive intensity will remain high, necessitating continuous product development and strategic marketing initiatives to capture significant market share. Recent developments include: July 2023: The Medicines and Healthcare Products Regulatory Agency (MHRA) started consulting on the reclassification of codeine linctus from over-the-counter in pharmacies to a prescription-only medicine., March 2023: The Commission on Human Medicines, the Medicines and Healthcare Products Regulatory Agency (MHRA) reclassified Cialis Together (tadalafil) so that it can be made available for purchase over the counter without a prescription.. Key drivers for this market are: Increasing Self-medication, Increasing Number of Product Launches. Potential restraints include: Increasing Self-medication, Increasing Number of Product Launches. Notable trends are: Analgesics are Expected to Hold a Significant Market Share Over the Forecast Period.

Since 2000, the annual sales value of over-the-counter (OTC) medicines in Great Britain has grown nearly year-on-year. At the start of the provided time interval, the sales value of OTC medicines was **** billion British pounds, and until 2024 this figure exceeded **** billion British pounds. OTC category breakdown From the **** billion pounds of sales value that OTC medicines amounted to in 2024, pain relief was the category with the highest sales value at some *** million pounds. The second-highest category was cough, cold, and sore throat remedies with a sales value of *** million pounds. Leading brands in the market In the UK, among the leading adult oral analgesics (also known as painkillers) brands by sales value was Nurofen with annual sales of around ** million British pounds. The pediatric analgesic market was dominated by Calpol, with annual sales of more than ** million British pounds.

Snapshot img

Over-The-Counter (OTC) Analgesics Market Size 2024-2028

The over-the-counter (OTC) analgesics market size is forecast to increase by USD 7.2 billion at a CAGR of 4.98% between 2023 and 2028.

The market is experiencing significant growth, driven by the increasing aging population worldwide and the rising number of product launches. The global population aged 60 and above is projected to more than double by 2050, creating a substantial demand for pain relief solutions. This demographic shift, coupled with the growing awareness and acceptance of self-care, is fueling the market's expansion. OTC drugs encompass a wide range of therapeutic areas, including analgesics, weight loss products, gastrointestinal products, skin products, mineral supplements, vitamin supplements, sleeping aids, ophthalmic products, sports nutrition, sports supplements, vitamins, minerals, amino acids, probiotics, omega-3 fatty acids, carbohydrates, and botanicals. However, the market's growth is not without challenges. The number of product recalls due to safety concerns and regulatory issues has been on the rise, posing significant risks for market players. These incidents can lead to reputational damage, regulatory penalties, and lost sales.
Companies must prioritize product safety and quality to mitigate these risks and maintain consumer trust. To capitalize on the market opportunities and navigate challenges effectively, companies should focus on innovation, regulatory compliance, and strategic partnerships. The market is responding to this trend with an expanding range of products and services, including over-the-counter medicines, and digital health solutions. Investing in research and development to launch new products that cater to the evolving consumer preferences and regulatory requirements can help companies stay competitive. Building strong relationships with regulatory bodies and industry associations can also help companies navigate the complex regulatory landscape and mitigate risks associated with product recalls. By addressing these challenges and leveraging market trends, companies can seize opportunities in the growing OTC Analgesics Market.

What will be the Size of the Over-The-Counter (OTC) Analgesics Market during the forecast period?

Request Free Sample

The market encompasses a wide range of pain medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs) and topical analgesics, designed to alleviate various types of pain, such as joint pain and chronic pain. These products are readily available in multiple distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. The geriatric population and the aging population are significant consumer groups, given the prevalence of joint pains and chronic conditions among older adults. Pregnant women also utilize OTC pain medicines for certain indications, following consultation with healthcare professionals.
Internal OTC analgesics and external OTC analgesics cater to different pain management needs. Off-label uses of these drugs continue to expand, reflecting the evolving role of OTC analgesics in pain management programs. The market's size and growth are influenced by factors such as increasing prevalence of chronic pain conditions, expanding distribution channels, and consumer preferences for self-care and convenience.

How is this Over-The-Counter (OTC) Analgesics Industry segmented?

The over-the-counter (OTC) analgesics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Internal
  External


Distribution Channel

  Offline
  Online


Form Factor

  Tablets and capsules
  Topical
  Syrups
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The internal segment is estimated to witness significant growth during the forecast period. The market encompasses internal and external analgesics used for pain relief. Internal analgesics, meant for ingestion, dominate the market, accounting for the largest share in 2023. Major drugs in this segment include acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen. Factors driving market growth include increasing pain-related conditions, self-medication trend, and healthcare expenditure. Key players invest in advertising campaigns to promote their brands, including Aleve, Advil, Crocin, MOTRIN, Aspirin, Excedrin, and TYLENOL. Chronic pain disorders, particularly among the geriatric population, pregnant women, and middle-lower class families, fuel demand for OTC analgesics. Distribution

Industry operators manufactures over-the-counter medication. Products manufactured by the industry are available without a prescription from pharmacies and grocery stores. Products include medication for pain relief, flu symptoms, and vitamins and minerals. The industry does not include companies that are primarily retailers, such as pharmacies and department stores.

Snapshot img

Over-The-Counter Drug Market Size 2025-2029

The over-the-counter (OTC) drug market size is forecast to increase by USD 59.6 billion at a CAGR of 6% between 2024 and 2029.

The market is experiencing significant growth dynamics, driven by the increasing number of geriatric populations worldwide. This demographic trend is fueling demand for self-care and self-medication solutions, particularly in the pharmaceutical sector. Digital health and personalized medicine are emerging areas, with artificial intelligence and machine learning playing significant roles in drug development and consumer education. Simultaneously, price sensitivity issues pose a challenge for OTC drug market players. As disposable income becomes a critical consideration for consumers, affordability remains a key factor influencing purchasing decisions. Navigating this market landscape requires strategic planning and a deep understanding of consumer behavior.
Simultaneously, addressing price sensitivity through competitive pricing strategies, value-added services, and innovative product offerings can help overcome this challenge. By staying attuned to these market drivers and trends, OTC drug market players can effectively position themselves to capitalize on opportunities and mitigate challenges in this dynamic market. Companies can capitalize on the growing geriatric population by developing products tailored to their unique needs and preferences. Consumer trends favor preventive care, leading to an increase in demand for nutritional supplements, vitamins, and other health and wellness products.

What will be the Size of the Over-The-Counter (OTC) Drug Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market encompasses a vast array of treatments for acute and chronic conditions, from symptom relief to disease management. The market's dynamics are shaped by various factors, including drug efficacy, personalized medicine, and consumer behavior. Public health initiatives prioritize disease prevention and management, driving demand for OTC medications. Risk management and international regulations play a crucial role in ensuring product safety and efficacy. Brand loyalty and consumer preferences influence market trends, with product differentiation and dosage guidelines shaping consumer choices. Health literacy and health insurance coverage also impact access to OTC drugs. Patent protection and intellectual property rights safeguard innovation, while healthcare access and medication assistance programs cater to underserved populations.

Product lifecycle management and adverse event reporting are essential for managing side effects and ensuring continuous improvement. Targeted therapies and disease management strategies are gaining traction, as personalized medicine becomes increasingly prevalent. Post-market surveillance and continuous monitoring are crucial for ensuring long-term safety and efficacy. Overall, the OTC drug market is a complex and evolving landscape, requiring effective risk management, consumer education, and regulatory oversight. Data analytics plays a crucial role in the development of these products, enabling companies to identify consumer preferences and tailor offerings accordingly.

How is this Over-The-Counter (OTC) Drug Industry segmented?

The over-the-counter (OTC) drug industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Distribution Channel

  Offline
  Online


Route Of Administration

  Oral
  Topical
  Parenteral


Formulation

  Tablets and capsules
  Liquids and syrups
  Creams and ointments
  Powders
  Sprays and drops


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period. The market in the US and Europe is characterized by a well-established distribution network, primarily relying on retail pharmacies for sales. These retail outlets include drugstores, supermarkets, hypermarkets, and convenience stores, which offer a wide range of OTC drugs. Walmart and Tesco plc lead the US market, while European supermarket giants like Tesco, Carrefour, and Aldi hold significant market share. Clinical trials ensure the safety and efficacy of OTC drugs, while quality control measures maintain consistency in product formulations. Ointment, tablet, capsule, and liquid formulations cater to diverse consumer needs. Topical medications, pain relievers, allergy medication

The United Kingdom OTC drugs market is anticipated to expand at a CAGR of 4.86% during the forecast period of 2025-2033. This growth can be attributed to factors such as the increasing prevalence of chronic diseases, rising disposable incomes, and growing awareness of self-medication. The market is also expected to benefit from the launch of new and innovative products, as well as the expansion of e-commerce channels. Within the OTC drugs market, the cough, cold, and flu products segment is expected to witness significant growth due to the increasing prevalence of respiratory illnesses. The analgesics segment is also expected to perform well, driven by the growing demand for pain relief medications. The market is dominated by a few major players, including Reckitt Benckiser Group PLC, Bayer AG, and Sanofi. However, there is also a significant presence of smaller, niche players that cater to specific customer segments. Recent developments include: July 2023: The Medicines and Healthcare Products Regulatory Agency (MHRA) started consulting on the reclassification of codeine linctus from over-the-counter in pharmacies to a prescription-only medicine., March 2023: The Commission on Human Medicines, the Medicines and Healthcare Products Regulatory Agency (MHRA) reclassified Cialis Together (tadalafil) so that it can be made available for purchase over the counter without a prescription.. Key drivers for this market are: Increasing Self-medication, Increasing Number of Product Launches. Potential restraints include: High Probability of OTC Drug Abuse and Lack of Awareness. Notable trends are: Analgesics are Expected to Hold a Significant Market Share Over the Forecast Period.

In UK Over The Counter Drugs Market , was valued at approximately USD 10.11 billion in 2022 and is projected to reach USD 12.45 billion by 2029,

Stock and commodity exchanges can benefit from various sources of revenue, ranging from fees charged through the purchasing and selling of stocks and commodities to the listing of companies on exchanges with IPOs. Yet, this hasn't meant exchanges have been free of challenges, with many companies looking to more attractive overseas markets in countries like the US that embrace stronger growth. The most notable culprits have been ARM and CRH, refusing to put up with the increasingly cheaper valuations offered by UK stock exchanges. Stock and commodity exchange revenue is expected to boom at a compound annual rate of 11.5% over the five years through 2024-25 to £15.4 billion. Boosted by the London Stock Exchange Group's Refinitiv purchase in 2021-22, the growth numbers seem inflated. The industry saw ample consolidations, aided by MiFID II's initiation in 2018. However, M&As have now decreased because of high borrowing costs. New reporting demands have bumped up regulatory costs, resulting in thinner profits. Banks, aligning with Basel IV, are pulling back on investments. Post-COVID market turbulence fuelled trades, but it's slowing down with economic stabilisation. The inflation slowdown pushes investors towards higher-value securities, boosting trade value despite lower volumes. The weak pound has been beneficial for revenue, especially for the LSEG, bolstered by dollar-earning companies in the FTSE 100. Stock and commodity exchange industry revenue is expected to show a moderate increase of 1.3% in 2024-25. Revenue is forecast to climb at a compound annual rate of 4.1% over the five years through 2029-30 to £18.8 billion. The cautious descent of interest rates from the Bank of England will slow down volatility and ensure greater business confidence in the UK. This will bring back up consolidation activity to support revenue growth, reviving the digital information and exchange markets. The most pressing concern for the industry will be potential limitations on access to the EEA for the clearing segment of the industry, which could shatter short-term growth and keep the tap running for companies exiting UK exchanges.

The average daily turnover of over the counter (OTC) derivatives traded in the United Kingdom rose steadily from 2001, and peaked in 2019. The total value of derivative turnovers in 2019 amounted to a value of around **** trillion U.S. dollars. The most common interest rate instruments traded were interest rate swaps. After only amounting to a value of *** billion U.S. dollars in 2001, the total value of interest rate swaps in 2019 amounted to over *** trillion U.S. dollars.

United Kingdom Over The Counter Drugs Market was valued at USD 4.03 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.75% through 2029.

This statistic displays the leading over-the-counter (OTC) pediatric analgesic brands in the United Kingdom (UK), by sales value in 2017. In this year Calpol dominated the analgesics for children market, with a sales value of approximately **** million British pounds.

Volatility in financial markets has been high in recent years, which has, at times, benefitted the brokerage industry through greater trading activity as investors look to capitalise on price swings. Most notably, the COVID-19 pandemic, the Ukraine conflict and aggressive interest hikes from Central Banks facing rampant inflation have incited severe volatility. Revenue is expected to grow at a compound annual rate of 2.7% over the five years through 2023-24 to £38.1 billion, including estimated growth of 3.9% in 2023-24. Although volatility can benefit the industry, it can also deter investors, incentivising them to delay investments until economic uncertainty subsides. In recent years, uncertainty has mainly stemmed from the aggressive interest rate hikes and their expected trajectory, hitting stock and bond markets in 2022 and hurting trading activity. Although interest rate uncertainty persisted going into 2023-24, stock markets improved thanks to exceptional growth from large-cap tech stocks and a sharp rally at the end of the year as investors bet on the end of rate hikes. Competition has softened as considerable consolidation activity has occurred between SMEs in the brokerage industry. However, the Markets in Financial Instruments Directive II has ramped up operating costs for brokerage firms, hurting profitability. Continued investment in software to help automate compliance procedures have benefitted margins, although the brokerage industry remains labour-intensive. Revenue is forecast to grow at a compound annual rate of 3.5% over the five years through 2028-29 to £45.2 billion, while the average industry profit margin is expected to reach 24.8%. The market narrative for interest rates is higher for longer, weighing on stock markets and hitting demand for brokers as trading activity slows. However, rate cuts are expected to occur in the second half of 2024-25, supporting bond values and stocks driving revenue growth in the short term. Further regulations related to Basel III are set to come into force in January 2025, adding pressure to brokers' operating costs. Due to Brexit, large international brokers are also shifting employees to overseas domiciles, adding downward pressure to revenue growth.

The global pet over-the-counter (OTC) medication market is expected to grow from USD 11.2 billion in 2025 to USD 16.5 billion by 2035, reflecting a steady CAGR of 5.1%.

Country-Wise Outlook

The pharmaceutical and healthcare supply chain is ever-changing. Wholesalers must follow and react to a dynamic environment with various regulations, licenses, taxation and shipping considerations. The loss of patent protection for several high-profile drugs has hampered performance because it has lowered revenue from such medications. Tighter regulation has pushed consumers towards generic medicines, increasing competition and lowering prices. This shift has squeezed profitability for wholesalers due to downward pricing pressure. Profitability should continue to recover as NHS budgets climb. Wholesalers will likely have adjusted to previous supply chain disruptions by then. Larger NHS budgets dedicated specifically to health and social care spending over the next few years should also support improved profit. Regulatory and funding challenges threaten wholesalers, favouring the retail of low-price generic drugs instead of high-end branded varieties. Over the five years through 2024-25, UK pharmaceutical wholesaling revenue is projected to climb at a compound annual rate of 0.8% to £64.2 billion. Government support has risen after several lean years, offering relief to the industry. Big manufacturers are shifting towards direct-to-pharmacy distribution, cutting out smaller wholesalers. This pushes smaller players to find niche areas and provide specialised logistics or patient support services to stay competitive. At the same time, online pharmacies are gaining traction, appealing especially to younger tech-savvy customers. Traditional pharmacies now have to build stronger online platforms or partner with established e-commerce setups to keep their relevance. Overall, increased NHS funding offers wholesaling opportunities, but rising medicine costs and tough price pressures remain significant barriers to entry, restricting new competitors. Industry revenue is expected to climb by 1% over 2024-25, supported by a resurgence in new orders from the dispensing chemist market. Over the five years through 2029-30, pharmaceutical wholesaling revenue is expected to surge at a compound annual rate of 5% to reach £82.1 billion. An ageing population, evolving attitudes towards healthcare, growing focus on personal well-being and continued product innovation will boost sales volumes and support growth prospects. With socio-economic and obesity-related illnesses like hypertension set to accelerate in the coming years, sales of pharmaceutical drugs like Wegovy will only climb. Despite the positive outlook, the industry will face numerous regulatory challenges, and some smaller wholesalers could struggle to attract customers amid intense pricing pressure.

In 2024, the consumer price index (CPI) of pharmaceutical products in the United Kingdom (UK) was measured at some 133. The CPI is designed to measure changes in the prices of goods that consumers buy. The year 2015 is used as the base year for calculations, and therefore the index in this year measures 100. UK OTC medication market The sales value of the British over-the-counter (OTC) medicines market has generally increased since 2000, amounting to a worth of approximately 4.1 billion British pounds in 2024. The category with the highest sales value among OTC medication in 2024 was pain relief, which accounted for nearly 860 million British pounds worth of sales. Prescribed medication At the same time as the OTC market has been growing, the number of prescription items dispensed also increased during this period. In 2023/24, the number of items dispensed in England showed a record high of 1.11 billion. The average number of prescription items dispensed per month at pharmacies in England came to over 7,100 in 2023/24.

The sales value of over-the-counter (OTC) cough, cold and sore throat treatments in Great Britain stood at over *** million British pounds in 2024. This was the highest value in the provided time interval. OTC medicine market in Great Britain  Cough, cold and sore throat medication had the second-highest sales value in 2024, when broken down by OTC drug categories. Pain relief medication was the category with the highest sales value, at approximately *** million British pounds. Vitamins and minerals had a sales value of *** million British pounds, the third-highest category overall in Great Britain. Overall, the sales value of OTC drugs has increased from **** billion British pounds in the year 2000 to over four billion British pounds in 2024.  Growth of other OTC categories The OTC product category which had the highest growth of sales value in Great Britain from 2023 and 2024 was cough and cold, with a significant growth of **** percent. This was followed by vitamins and minerals, which grew by ***** percent compared to the previous year. 

Over the five years through 2024-25, dispensing chemists’ revenue is expected to dip at a compound annual rate of 0.4% to £14.1 billion. Revenue growth has come under intense pricing pressure due to regulatory amendments and the loss of patent protection. The government and industry bodies have fought to save dispensing chemists in light of these challenging conditions, through initiatives like the Pharmacy Access Scheme, NHS Urgent Medicine Supply Advanced Service and the Quality Payment Schemes. In November 2024, the Royal Pharmaceutical Society called for mass change and a cohesive cross-government and NHS strategy to improve medicines’ supply chain resilience and security moving forward. Larger pharmacies have branched out with a range of platforms where they offer goods and services, dipping their toes in the water of mobile apps and next-day delivery. Sales have been boosted through digital services like Boots ' Online Health Hub giving customers access to digital healthcare solutions. Online doctors and virtual GP consultations have provided consumers with quick and easy prescription medicines, supporting sales of prescription-only products. Still, in 2023-24, revenue tanked amid falling disposable incomes, insufficient government funding and the loss of LloydsPharmacy's high-street operations. Consolidation activity and own-brand product marketing are expected to drive growth of 1.7% in 2024-25, although the loss of government funding and medicine shortages are weighing on profitability. As of February 2025, the government has still not renewed CPCF funding arrangements, meaning pharmacies have been working without a new contract since April 2024. Over the five years through 2029-30, revenue is anticipated to swell at a compound annual rate of 3.6% to £16.9 billion. Branching out into new services, digitalisation, a growing and ageing population, ever-growing health consciousness and the rising prevalence of obesity offer avenues for growth in the coming years. The future of the UK’s trade relationship with the UK could also be a major driver of the industry’s performance; if Trump does impose tariffs on UK pharmaceutical exports, then this could help to mitigate some of the medicinal supply issues being faced by chemists in the UK, as UK pharmaceutical manufacturers may redirect their products to UK chemists to offset the loss in demand from US exports. However, challenges remain; external competition from supermarkets and online-only pharmacies is set to intensify as potential new digital chemists like Amazon Pharmacy enter the market, stealing sales from bricks-and-mortar stores. Stringent regulation, structural changes and employment pressures will limit revenue growth. Low-cost generic drugs will continue to flood the market as pharmaceutical patents expire, boosting price competition.